Reported 5 months ago
The Motley Fool article discusses three key points to consider if buying Novavax stock. Novavax has recently formed a partnership with Sanofi, which may boost revenue growth, especially through combination vaccines. The company has taken steps to improve profitability and reduce expenses, with the potential for significant royalty payments from Sanofi. Novavax's focus on combination vaccines, particularly COVID/flu shots, could be a game-changer. While Novavax's recovery story seems promising, it may still take time for market share to establish, but with the positive direction and a strong partner like Sanofi, the stock may present a promising recovery investment opportunity.
Source: YAHOO